Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Weichenthal

Showing results (51-60 of 54) with videos related to

Pageof 6
Sort By:
You have reached the last page of results.This site can display upto 54 results.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III studyM F Avril, S Aamdal, J J Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2024
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncologyL Kandolf, P A Ascierto, L Bastholt, et al.
The British Journal of Dermatology|September 30, 2018
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patientsJ J Scarisbrick, P Quaglino, H M Prince, et al.
Pageof 6

Showing results (51-60 of 54) with videos related to

Sort By:
Pageof 6
You have reached the last page of results.This site can display upto 54 results.
European Journal of Cancer (Oxford, England : 1990)|December 12, 2025
Characteristics and quality of life of nine-year survivors with metastatic melanoma treated with pembrolizumab beyond second-line therapyS Dugas-Breit, A Forschner, M Erdmann, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 17, 2004
Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III studyM F Avril, S Aamdal, J J Grob, et al.
European Journal of Cancer (Oxford, England : 1990)|December 25, 2024
An update on access to novel treatment for metastatic melanoma in Europe - A 2024 survey of the European melanoma registry and the European association of dermato-oncologyL Kandolf, P A Ascierto, L Bastholt, et al.
The British Journal of Dermatology|September 30, 2018
The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patientsJ J Scarisbrick, P Quaglino, H M Prince, et al.
Pageof 6